ArticleCureus2026
Paget's Disease Unveiled in a Primary Care Setting: A Case of High Alkaline Phosphatase.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paget's disease of bone (PDB) is a moderately common clinical entity that causes bone deformities and focal areas of disorganized new bone formation. It is characterized by abnormal bone remodeling, leading to enlarged and weakened bones. Although often asymptomatic, it can present with localized pain, deformity, or fractures. Elevated alkaline phosphatase (ALP) levels, which are bone-specific, are common biochemical findings of PDB and can be treated with bisphosphonates; however, diagnosing it based on clinical presentation may be challenging due to the asymptomatic nature of the disease, as well as the various factors, causes, and tests required for an accurate diagnosis. We present the case of a 67-year-old male patient who initially presented to the clinic with a right heel fracture and right hip pain, which turned out to be PDB marked by an increased ALP level. A radionuclide bone scan confirmed right pelvic bone deformity and prompted the prescription of zoledronic acid. Lab work was repeated six months later, and a repeat radionuclide bone scan will be performed if the patient experiences any new symptoms. With such cases often being overlooked, especially in primary care settings, this report emphasizes the vital need to monitor biochemical markers, such as ALP. This report highlights the diagnostic process and clinical considerations involved in identifying and managing PDB.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.